MA51826A - Compositions pharmaceutiques comprenant de la teixobactine - Google Patents
Compositions pharmaceutiques comprenant de la teixobactineInfo
- Publication number
- MA51826A MA51826A MA051826A MA51826A MA51826A MA 51826 A MA51826 A MA 51826A MA 051826 A MA051826 A MA 051826A MA 51826 A MA51826 A MA 51826A MA 51826 A MA51826 A MA 51826A
- Authority
- MA
- Morocco
- Prior art keywords
- teixobactine
- pharmaceutical compositions
- compositions including
- pharmaceutical
- including teixobactine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631100P | 2018-02-15 | 2018-02-15 | |
| US201862687950P | 2018-06-21 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51826A true MA51826A (fr) | 2020-12-23 |
Family
ID=65494607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051826A MA51826A (fr) | 2018-02-15 | 2019-02-06 | Compositions pharmaceutiques comprenant de la teixobactine |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12036264B2 (fr) |
| EP (1) | EP3752148A1 (fr) |
| JP (1) | JP7296394B2 (fr) |
| AU (1) | AU2019222508B2 (fr) |
| CA (1) | CA3090670A1 (fr) |
| MA (1) | MA51826A (fr) |
| WO (1) | WO2019160719A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11802170B2 (en) | 2021-04-29 | 2023-10-31 | Exxonmobil Chemical Patents Inc. | Polyolefins prepared with binuclear metallocene catalysts |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040116360A1 (en) * | 2002-10-15 | 2004-06-17 | Kwon Glen S. | Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles |
| WO2011160110A1 (fr) * | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Nouvelle formulation d'antibiotiques de glycopeptides encapsulés dans des liposomes pegylés |
| EP4414376A3 (fr) | 2012-12-03 | 2024-11-06 | Novobiotic Pharmaceuticals, LLC | Nouveau depsipeptide et ses utilisations |
-
2019
- 2019-02-06 JP JP2020543489A patent/JP7296394B2/ja active Active
- 2019-02-06 WO PCT/US2019/016796 patent/WO2019160719A1/fr not_active Ceased
- 2019-02-06 CA CA3090670A patent/CA3090670A1/fr active Pending
- 2019-02-06 AU AU2019222508A patent/AU2019222508B2/en active Active
- 2019-02-06 MA MA051826A patent/MA51826A/fr unknown
- 2019-02-06 US US16/969,598 patent/US12036264B2/en active Active
- 2019-02-06 EP EP19706167.4A patent/EP3752148A1/fr active Pending
-
2024
- 2024-05-03 US US18/654,900 patent/US20240293502A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021513971A (ja) | 2021-06-03 |
| EP3752148A1 (fr) | 2020-12-23 |
| US12036264B2 (en) | 2024-07-16 |
| US20240293502A1 (en) | 2024-09-05 |
| CA3090670A1 (fr) | 2019-08-22 |
| WO2019160719A1 (fr) | 2019-08-22 |
| US20210052693A1 (en) | 2021-02-25 |
| JP7296394B2 (ja) | 2023-06-22 |
| WO2019160719A9 (fr) | 2020-08-13 |
| AU2019222508B2 (en) | 2024-11-14 |
| AU2019222508A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3817722A4 (fr) | Compositions pharmaceutiques comprenant du méloxicam | |
| MA52421A (fr) | Composés pharmaceutiques | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| EP3641771A4 (fr) | Compositions pharmaceutiques | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| MA49977A (fr) | Combinaisons pharmaceutiques comprenant un anticorps anti-ly75 | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| EP3573614C0 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| EP3914234A4 (fr) | Compositions pharmaceutiques | |
| EP3897593A4 (fr) | Formulations de cannabinoïdes et compositions pharmaceutiques | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| EP3389633A4 (fr) | Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine | |
| EP4015001A4 (fr) | Composition pharmaceutique orale | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| MA44010A (fr) | Formulations pharmaceutiques de billes comprenant du diméthylfumarate | |
| EP3337463A4 (fr) | Formulations pharmaceutiques | |
| MA53812A (fr) | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques | |
| MA54095A (fr) | Formulations pharmaceutiques aqueuses | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| EP3920909A4 (fr) | Compositions pharmaceutiques comprenant du méloxicam | |
| PT3949952T (pt) | Composição farmacêutica | |
| EP3881841A4 (fr) | Composition pharmaceutique | |
| PL3787596T3 (pl) | Ulepszone formulacje farmaceutyczne |